Item Type | Name |
Concept
|
Abdominal Neoplasms
|
Concept
|
Antigens, Neoplasm
|
Concept
|
Antibodies, Neoplasm
|
Concept
|
Breast Neoplasms
|
Concept
|
Bone Neoplasms
|
Concept
|
Urinary Bladder Neoplasms
|
Concept
|
Colonic Neoplasms
|
Concept
|
DNA, Neoplasm
|
Concept
|
Kidney Neoplasms
|
Concept
|
Mammary Neoplasms, Experimental
|
Concept
|
Eye Neoplasms
|
Concept
|
Liver Neoplasms
|
Concept
|
Neoplasm Transplantation
|
Concept
|
Pancreatic Neoplasms
|
Concept
|
Wilms Tumor
|
Concept
|
Neoplasm Staging
|
Concept
|
Lung Neoplasms
|
Concept
|
Mediastinal Neoplasms
|
Concept
|
Prostatic Neoplasms
|
Concept
|
Head and Neck Neoplasms
|
Concept
|
Thymus Neoplasms
|
Concept
|
Biomarkers, Tumor
|
Concept
|
Tumor Necrosis Factor-alpha
|
Concept
|
Drug Resistance, Neoplasm
|
Concept
|
Tumor Cells, Cultured
|
Concept
|
Lymphocytes, Tumor-Infiltrating
|
Concept
|
Neoplasm Metastasis
|
Concept
|
Neoplasm Recurrence, Local
|
Concept
|
Neoplasms, Experimental
|
Concept
|
Cancer Vaccines
|
Concept
|
Tumor Necrosis Factor Receptor Superfamily, Member 9
|
Concept
|
Tumor Burden
|
Concept
|
Tumor Escape
|
Concept
|
Tumor Necrosis Factor Ligand Superfamily Member 14
|
Concept
|
National Cancer Institute (U.S.)
|
Concept
|
Skin Neoplasms
|
Concept
|
Spinal Cord Neoplasms
|
Concept
|
Hematologic Neoplasms
|
Concept
|
Tumor Microenvironment
|
Concept
|
Cell Line, Tumor
|
Concept
|
Brain Neoplasms
|
Concept
|
Neoplasm Invasiveness
|
Concept
|
Neoplasm Proteins
|
Concept
|
Neoplasms
|
Concept
|
Uveal Neoplasms
|
Concept
|
Neoplasm, Residual
|
Academic Article
|
B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro.
|
Academic Article
|
Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization.
|
Academic Article
|
Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A.
|
Academic Article
|
Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo.
|
Academic Article
|
Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells.
|
Academic Article
|
Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice.
|
Academic Article
|
The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen.
|
Academic Article
|
Rational development of tumour antigen-specific immunization in melanoma.
|
Academic Article
|
The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response.
|
Academic Article
|
Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity.
|
Academic Article
|
Allogeneic peripheral blood stem cell transplantation for metastatic renal cell carcinoma.
|
Academic Article
|
Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1.
|
Academic Article
|
Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond.
|
Academic Article
|
Biochemical analysis of activated T lymphocytes. Protein phosphorylation and Ras, ERK, and JNK activation.
|
Academic Article
|
Polymyositis with respiratory muscle weakness requiring mechanical ventilation in a patient with metastatic thymoma treated with octreotide.
|
Academic Article
|
B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells.
|
Academic Article
|
Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12.
|
Academic Article
|
Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results.
|
Academic Article
|
Flt-3 ligand and sequential FL/interleukin-2 in patients with metastatic renal carcinoma: clinical and biologic activity.
|
Academic Article
|
Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152).
|
Academic Article
|
Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.
|
Academic Article
|
Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice.
|
Academic Article
|
Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.
|
Academic Article
|
B7DC/PDL2 promotes tumor immunity by a PD-1-independent mechanism.
|
Academic Article
|
Integrating IL-12 into therapeutic cancer vaccines.
|
Academic Article
|
Absence of CTLA-4 lowers the activation threshold of primed CD8+ TCR-transgenic T cells: lack of correlation with Src homology domain 2-containing protein tyrosine phosphatase.
|
Academic Article
|
Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A.
|
Academic Article
|
Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells.
|
Academic Article
|
Semiquantitative analysis of dynamic contrast enhanced MRI in cancer patients: Variability and changes in tumor tissue over time.
|
Academic Article
|
Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells.
|
Academic Article
|
Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago Experience.
|
Academic Article
|
Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
|
Academic Article
|
Disparate functions of immature and mature human myeloid dendritic cells: implications for dendritic cell-based vaccines.
|
Academic Article
|
Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells.
|
Academic Article
|
Update on vaccines for solid tumors.
|
Academic Article
|
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro.
|
Academic Article
|
Innovations and challenges in melanoma: summary statement from the first Cambridge conference.
|
Academic Article
|
On the TRAIL toward death receptor-based cancer therapeutics.
|
Academic Article
|
Phase 2 study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901.
|
Academic Article
|
Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection.
|
Academic Article
|
Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea in advanced melanoma.
|
Academic Article
|
Immune suppression in the tumor microenvironment.
|
Academic Article
|
Tumor progression despite massive influx of activated CD8(+) T cells in a patient with malignant melanoma ascites.
|
Academic Article
|
The p815 mastocytoma tumor model.
|
Academic Article
|
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
|
Academic Article
|
Homeostatic proliferation plus regulatory T-cell depletion promotes potent rejection of B16 melanoma.
|
Academic Article
|
Melanoma presenting as circulating tumor cells associated with failed angiogenesis.
|
Academic Article
|
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
|
Academic Article
|
The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer.
|
Academic Article
|
Metabolic mechanisms of tumor resistance to T cell effector function.
|
Academic Article
|
Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.
|
Academic Article
|
Negative regulation of T-cell function by PD-1.
|
Academic Article
|
Anti-proliferative effect of IFN-gamma in immune regulation. IV. Murine CTL clones produce IL-3 and GM-CSF, the activity of which is masked by the inhibitory action of secreted IFN-gamma.
|
Academic Article
|
A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.
|
Academic Article
|
Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.
|
Academic Article
|
Immune resistance orchestrated by the tumor microenvironment.
|
Academic Article
|
A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanoma.
|
Academic Article
|
Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
|
Academic Article
|
Homeostatic proliferation of naïve CD8+ T cells depends on CD62L/L-selectin-mediated homing to peripheral LN.
|
Academic Article
|
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.
|
Academic Article
|
Gene signature in melanoma associated with clinical activity: a potential clue to unlock cancer immunotherapy.
|
Academic Article
|
Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy.
|
Academic Article
|
Emerging strategies in regulatory T-cell immunotherapies.
|
Academic Article
|
Costimulatory and coinhibitory receptors in anti-tumor immunity.
|
Academic Article
|
Molecular profiling of melanoma and the evolution of patient-specific therapy.
|
Academic Article
|
The immune score as a new possible approach for the classification of cancer.
|
Academic Article
|
Innate immune sensing of cancer: clues from an identified role for type I IFNs.
|
Academic Article
|
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".
|
Academic Article
|
Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.
|
Academic Article
|
ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo.
|
Academic Article
|
Costimulation with B7-1, IL-6, and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro.
|
Academic Article
|
Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer.
|
Academic Article
|
Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells.
|
Academic Article
|
Defining the critical hurdles in cancer immunotherapy.
|
Academic Article
|
Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases.
|
Academic Article
|
From defined human tumor antigens to effective immunization?
|
Academic Article
|
The expanding universe of regulatory T cell subsets in cancer.
|
Academic Article
|
CARMA1 controls an early checkpoint in the thymic development of FoxP3+ regulatory T cells.
|
Academic Article
|
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery.
|
Academic Article
|
Cellular and molecular requirements for rejection of B16 melanoma in the setting of regulatory T cell depletion and homeostatic proliferation.
|
Academic Article
|
A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3.
|
Academic Article
|
Regulation of anti-immunoglobulin-induced B lymphoma growth arrest by transforming growth factor beta 1 and dexamethasone.
|
Academic Article
|
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells.
|
Academic Article
|
A phase II study of bryostatin-1 and paclitaxel in patients with advanced non-small cell lung cancer.
|
Academic Article
|
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells.
|
Academic Article
|
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
|
Academic Article
|
Overcoming immune resistance in the tumor microenvironment by blockade of indoleamine 2,3-dioxygenase and programmed death ligand 1.
|
Academic Article
|
Lymphoma-infiltrating immune cells.
|
Academic Article
|
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.
|
Academic Article
|
Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics.
|
Academic Article
|
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.
|
Academic Article
|
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.
|
Academic Article
|
Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
|
Academic Article
|
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment.
|
Academic Article
|
Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer.
|
Academic Article
|
Ocular melanoma metastasis to the cervical spine.
|
Academic Article
|
Cancer immunotherapy.
|
Academic Article
|
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
|
Academic Article
|
[Osteoid osteoma].
|
Academic Article
|
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".
|
Academic Article
|
Cancer classification using the Immunoscore: a worldwide task force.
|
Academic Article
|
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.
|
Academic Article
|
Type I interferon response and innate immune sensing of cancer.
|
Academic Article
|
Cancer immunotherapy.
|
Academic Article
|
Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104).
|
Academic Article
|
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment.
|
Academic Article
|
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
|
Academic Article
|
Targeting the tumor microenvironment with interferon-ß bridges innate and adaptive immune responses.
|
Academic Article
|
Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
|
Academic Article
|
Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
|
Academic Article
|
Therapeutic activity of high-dose intratumoral IFN-ß requires direct effect on the tumor vasculature.
|
Academic Article
|
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
|
Academic Article
|
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
|
Academic Article
|
New perspectives on type I IFNs in cancer.
|
Academic Article
|
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
|
Academic Article
|
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
|
Academic Article
|
Innate immune recognition of cancer.
|
Academic Article
|
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
|
Academic Article
|
T cell-NF-?B activation is required for tumor control in vivo.
|
Academic Article
|
Innate and adaptive immune cells in the tumor microenvironment.
|
Academic Article
|
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.
|
Academic Article
|
A randomized pilot phase I study of modified carcinoembryonic antigen (CEA) peptide (CAP1-6D)/montanide/GM-CSF-vaccine in patients with pancreatic adenocarcinoma.
|
Academic Article
|
Rational combinations of immunotherapeutics that target discrete pathways.
|
Academic Article
|
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
|
Academic Article
|
Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition.
|
Academic Article
|
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.
|
Academic Article
|
The STING pathway and the T cell-inflamed tumor microenvironment.
|
Academic Article
|
Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints.
|
Academic Article
|
Melanoma-intrinsic ß-catenin signalling prevents anti-tumour immunity.
|
Academic Article
|
The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.
|
Academic Article
|
A new paradigm for tumor immune escape: ß-catenin-driven immune exclusion.
|
Academic Article
|
Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
|
Academic Article
|
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
|
Academic Article
|
Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy.
|
Academic Article
|
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014.
|
Academic Article
|
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
|
Academic Article
|
A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.
|
Academic Article
|
Cutting Edge: Engineering Active IKKß in T Cells Drives Tumor Rejection.
|
Academic Article
|
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.
|
Academic Article
|
Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA.
|
Academic Article
|
Germ Warfare.
|
Academic Article
|
MYC - a thorn in the side of cancer immunity.
|
Academic Article
|
Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial.
|
Academic Article
|
Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer.
|
Academic Article
|
The host STING pathway at the interface of cancer and immunity.
|
Academic Article
|
Manipulating the microbiome to improve the efficacy of immunotherapy.
|
Academic Article
|
NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells.
|
Academic Article
|
Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy.
|
Academic Article
|
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
|
Academic Article
|
Lymphatic vessels regulate immune microenvironments in human and murine melanoma.
|
Academic Article
|
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
|
Academic Article
|
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.
|
Academic Article
|
Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.
|
Academic Article
|
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition.
|
Academic Article
|
Innate immune signaling and regulation in cancer immunotherapy.
|
Academic Article
|
First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
|
Academic Article
|
Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk.
|
Academic Article
|
The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.
|
Academic Article
|
Tumor-intrinsic oncogene pathways mediating immune avoidance.
|
Academic Article
|
Reciprocal expression of indoleamine-2,3-dioxygenase (IDO) and arginase-I in metastatic melanoma tumors.
|
Academic Article
|
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.
|
Academic Article
|
Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-a2b in patients with metastatic melanoma.
|
Academic Article
|
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.
|
Academic Article
|
The Microbiota: A New Variable Impacting Cancer Treatment Outcomes.
|
Academic Article
|
Impact of oncogenic pathways on evasion of antitumour immune responses.
|
Academic Article
|
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).
|
Academic Article
|
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
|
Academic Article
|
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies.
|
Academic Article
|
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
|
Academic Article
|
Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity.
|
Academic Article
|
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.
|
Academic Article
|
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.
|
Academic Article
|
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037).
|
Academic Article
|
Back from the dead: TIL apoptosis in cancer immune evasion.
|
Academic Article
|
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
|
Academic Article
|
Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.
|
Academic Article
|
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors.
|
Academic Article
|
Fast Forward - Neoadjuvant Cancer Immunotherapy.
|
Academic Article
|
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
|
Academic Article
|
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.
|
Academic Article
|
Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
|
Academic Article
|
High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions.
|
Academic Article
|
WNT/ß-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers.
|
Academic Article
|
Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.
|
Academic Article
|
Brain Tumor Microenvironment and Host State: Implications for Immunotherapy.
|
Academic Article
|
Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma.
|
Academic Article
|
Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy).
|
Academic Article
|
STING pathway agonism as a cancer therapeutic.
|
Academic Article
|
Secondary resistance to immunotherapy associated with ß-catenin pathway activation or PTEN loss in metastatic melanoma.
|
Academic Article
|
Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.
|
Academic Article
|
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.
|
Academic Article
|
Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-?-signaling mutant cancer cells.
|
Academic Article
|
Exploring the emerging role of the microbiome in cancer immunotherapy.
|
Academic Article
|
A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab.
|
Academic Article
|
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.
|
Academic Article
|
Strategies to overcome resistance to PD-1 inhibitors.
|
Academic Article
|
cDC1 dysregulation in cancer: An opportunity for intervention.
|
Academic Article
|
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy).
|
Academic Article
|
Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion.
|
Academic Article
|
Improved Survival Associated with Local Tumor Response Following Multisite Radiotherapy and Pembrolizumab: Secondary Analysis of a Phase I Trial.
|
Academic Article
|
Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy.
|
Academic Article
|
Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients.
|
Academic Article
|
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy).
|
Academic Article
|
Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma.
|
Academic Article
|
Immune cell and tumor cell-derived CXCL10 is indicative of immunotherapy response in metastatic melanoma.
|
Academic Article
|
PAK4 as a cancer immune-evasion target.
|
Academic Article
|
Dietary modulation of the gut microbiome as an immunoregulatory intervention.
|
Academic Article
|
Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration.
|
Academic Article
|
Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies.
|
Academic Article
|
Microbiome-based interventions: therapeutic strategies in cancer immunotherapy.
|
Academic Article
|
CXCL9 and CXCL10 bring the heat to tumors.
|
Academic Article
|
Checkpoint Blockade-Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines.
|
Academic Article
|
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd - 4th, 2021, Italy).
|
Academic Article
|
Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit.
|
Academic Article
|
Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade.
|
Academic Article
|
Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events.
|
Concept
|
Response Evaluation Criteria in Solid Tumors
|
Academic Article
|
Tissue-resident memory T cells in immune-related adverse events: friend or foe?
|
Academic Article
|
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition.
|
Academic Article
|
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
|